FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947186761> ?p ?o ?g. }

• W2947186761 endingPage "TPS4164" @default.
• W2947186761 startingPage "TPS4164" @default.
• W2947186761 abstract "TPS4164 Background: Local progression causes up to 30% of deaths from pancreatic cancer (PC) and is also a significant source of morbidity. Stereotactic body radiotherapy (SBRT) offers the potential for improved therapeutic index over standard fractionation, but current regimens of 5-7 Gy/fraction x 5 are constrained by nearby organ tolerance and offer only palliation without improving survival. Safe dose escalation is necessary to improve SBRT efficacy. GC4419, a superoxide dismutase mimetic, selectively converts superoxide (O2•-) to hydrogen peroxide (H2O2) and oxygen. O2•-initiates normal tissue damage due to RT. GC4419 is in a Phase 3 trial (NCT03689712) to reduce RT-induced oral mucositis in head and neck cancer, based on positive results in a randomized Phase 2 trial for that indication (Anderson, ASCO 2018). GC4419 improved the survival of mice receiving 8.5 Gy x 5 to the upper abdomen. Cancer cells are less tolerant to elevated H2O2, and more tolerant to elevated O2•-, than normal cells, and GC4419 demonstrated mechanism-dependent synergy with high dose-fraction RT in a human tumor xenograft with inducible expression of catalase (Sishc, AACR 2018). Thus, adding GC4419 to SBRT may increase both the efficacy and the safety of the latter. Methods: 48 patients with localized, unresectable PC without frank duodenal invasion, who have received 3+ cycles of induction chemotherapy, are to be randomized 1:1 to placebo or GC4419, 90 mg IV, prior to each of 5 consecutive daily (M-F) SBRT fractions. A phase I/II Late Onset Efficacy/ Toxicity tradeoff (LO-ET) based adaptive design adaptive model drives SBRT dose escalation in each arm based on a dual endpoint (Gr 3-4 GI toxicity or death ;stable disease or better) by 90 days post SBRT. The planned dose levels are 10, 11 and 12Gy x 5 fractions (BED10=100,112.5 and 132Gy, respectively) as an integrated boost to the gross tumor volume (GTV). Primary endpoint: Maximum tolerated dose of SBRT with GC4419 or placebo. Exploratory endpoints include change in tumor radiographic resectability, correlative studies (ctDNA, exosomal DNA, tumor exome/transcriptome sequencing, immune profiling). Supported by Galera Therapeutics, Inc. Clinical trial information: NCT03340974." @default.
• W2947186761 created "2019-06-07" @default.
• W2947186761 creator A5002347804 @default.
• W2947186761 creator A5011254389 @default.
• W2947186761 creator A5022738159 @default.
• W2947186761 creator A5036220343 @default.
• W2947186761 creator A5057774493 @default.
• W2947186761 creator A5065934113 @default.
• W2947186761 creator A5079075847 @default.
• W2947186761 creator A5081388353 @default.
• W2947186761 creator A5088853428 @default.
• W2947186761 creator A5089299130 @default.
• W2947186761 date "2019-05-20" @default.
• W2947186761 modified "2023-09-26" @default.
• W2947186761 title "Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer." @default.
• W2947186761 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.tps4164" @default.
• W2947186761 hasPublicationYear "2019" @default.
• W2947186761 type Work @default.
• W2947186761 sameAs 2947186761 @default.
• W2947186761 citedByCount "1" @default.
• W2947186761 countsByYear W29471867612021 @default.
• W2947186761 crossrefType "journal-article" @default.
• W2947186761 hasAuthorship W2947186761A5002347804 @default.
• W2947186761 hasAuthorship W2947186761A5011254389 @default.
• W2947186761 hasAuthorship W2947186761A5022738159 @default.
• W2947186761 hasAuthorship W2947186761A5036220343 @default.
• W2947186761 hasAuthorship W2947186761A5057774493 @default.
• W2947186761 hasAuthorship W2947186761A5065934113 @default.
• W2947186761 hasAuthorship W2947186761A5079075847 @default.
• W2947186761 hasAuthorship W2947186761A5081388353 @default.
• W2947186761 hasAuthorship W2947186761A5088853428 @default.
• W2947186761 hasAuthorship W2947186761A5089299130 @default.
• W2947186761 hasConcept C121608353 @default.
• W2947186761 hasConcept C126322002 @default.
• W2947186761 hasConcept C126894567 @default.
• W2947186761 hasConcept C143998085 @default.
• W2947186761 hasConcept C2776694085 @default.
• W2947186761 hasConcept C2778424827 @default.
• W2947186761 hasConcept C2778496288 @default.
• W2947186761 hasConcept C2780210213 @default.
• W2947186761 hasConcept C2780258809 @default.
• W2947186761 hasConcept C509974204 @default.
• W2947186761 hasConcept C71924100 @default.
• W2947186761 hasConcept C90924648 @default.
• W2947186761 hasConceptScore W2947186761C121608353 @default.
• W2947186761 hasConceptScore W2947186761C126322002 @default.
• W2947186761 hasConceptScore W2947186761C126894567 @default.
• W2947186761 hasConceptScore W2947186761C143998085 @default.
• W2947186761 hasConceptScore W2947186761C2776694085 @default.
• W2947186761 hasConceptScore W2947186761C2778424827 @default.
• W2947186761 hasConceptScore W2947186761C2778496288 @default.
• W2947186761 hasConceptScore W2947186761C2780210213 @default.
• W2947186761 hasConceptScore W2947186761C2780258809 @default.
• W2947186761 hasConceptScore W2947186761C509974204 @default.
• W2947186761 hasConceptScore W2947186761C71924100 @default.
• W2947186761 hasConceptScore W2947186761C90924648 @default.
• W2947186761 hasIssue "15_suppl" @default.
• W2947186761 hasLocation W29471867611 @default.
• W2947186761 hasOpenAccess W2947186761 @default.
• W2947186761 hasPrimaryLocation W29471867611 @default.
• W2947186761 hasRelatedWork W114644245 @default.
• W2947186761 hasRelatedWork W2097853395 @default.
• W2947186761 hasRelatedWork W2376347278 @default.
• W2947186761 hasRelatedWork W2397916166 @default.
• W2947186761 hasRelatedWork W2404042595 @default.
• W2947186761 hasRelatedWork W2997709950 @default.
• W2947186761 hasRelatedWork W3021135223 @default.
• W2947186761 hasRelatedWork W3029364823 @default.
• W2947186761 hasRelatedWork W3128748660 @default.
• W2947186761 hasRelatedWork W72446658 @default.
• W2947186761 hasVolume "37" @default.
• W2947186761 isParatext "false" @default.
• W2947186761 isRetracted "false" @default.
• W2947186761 magId "2947186761" @default.
• W2947186761 workType "article" @default.